| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 975 | 2022 |
| Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, ... Nature 603 (7902), 700-705, 2022 | 630 | 2022 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Cell 185 (12), 2103-2115. e19, 2022 | 298 | 2022 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA. 4 and BA. 5 I Kimura, D Yamasoba, T Tamura, N Nao, T Suzuki, Y Oda, S Mitoma, J Ito, ... Cell 185 (21), 3992-4007. e16, 2022 | 254 | 2022 |
| Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies D Yamasoba, Y Kosugi, I Kimura, S Fujita, K Uriu, J Ito, K Sato The Lancet Infectious Diseases 22 (7), 942-943, 2022 | 219 | 2022 |
| The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... Cell reports 38 (2), 2022 | 207 | 2022 |
| Virological characteristics of the SARS-CoV-2 JN. 1 variant Y Kaku, K Okumura, M Padilla-Blanco, Y Kosugi, K Uriu, AA Hinay, ... The Lancet Infectious Diseases 24 (2), e82, 2024 | 202 | 2024 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2.75 variant A Saito, T Tamura, J Zahradnik, S Deguchi, K Tabata, Y Anraku, I Kimura, ... Cell host & microbe 30 (11), 1540-1555. e15, 2022 | 138 | 2022 |
| Virological characteristics of the SARS-CoV-2 omicron XBB. 1.16 variant D Yamasoba, K Uriu, A Plianchaisuk, Y Kosugi, L Pan, J Zahradnik, J Ito, ... The Lancet Infectious Diseases 23 (6), 655-656, 2023 | 125 | 2023 |
| SARS-CoV-2 Omicron spike mediated immune escape and tropism shift B Meng, IATM Ferreira, A Abdullahi, N Goonawardane, A Saito, I Kimura, ... BioRxiv, 2021.12. 17.473248, 2021 | 107 | 2021 |
| Virological characteristics of SARS-CoV-2 BA. 2 variant D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... BioRxiv, 2022.02. 14.480335, 2022 | 102 | 2022 |
| Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk F Sekiguchi, R Domoto, K Nakashima, D Yamasoba, H Yamanishi, ... Neuropharmacology 141, 201-213, 2018 | 86 | 2018 |
| N4BP1 restricts HIV-1 and its inactivation by MALT1 promotes viral reactivation D Yamasoba, K Sato, T Ichinose, T Imamura, L Koepke, S Joas, E Reith, ... Nature Microbiology 4 (9), 1532-1544, 2019 | 82 | 2019 |
| Peripheral HMGB1-induced hyperalgesia in mice: Redox state-dependent distinct roles of RAGE and TLR4 D Yamasoba, M Tsubota, R Domoto, F Sekiguchi, H Nishikawa, K Liu, ... Journal of pharmacological sciences 130 (2), 139-142, 2016 | 58 | 2016 |
| Virological characteristics of the SARS-CoV-2 KP. 2 variant Y Kaku, K Uriu, Y Kosugi, K Okumura, D Yamasoba, Y Uwamino, ... The Lancet Infectious Diseases 24 (7), e416, 2024 | 56 | 2024 |
| Regnase-1 and roquin nonredundantly regulate Th1 differentiation causing cardiac inflammation and fibrosis X Cui, T Mino, M Yoshinaga, Y Nakatsuka, F Hia, D Yamasoba, ... The Journal of Immunology 199 (12), 4066-4077, 2017 | 53 | 2017 |
| Genotype to Phenotype Japan (G2P-Japan) Consortium. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies D Yamasoba, Y Kosugi, I Kimura, S Fujita, K Uriu, J Ito, K Sato Lancet Infect. Dis 22 (7), 942-943, 2022 | 52* | 2022 |
| Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA. 2.12. 1 I Kimura, D Yamasoba, T Tamura, N Nao, Y Oda, S Mitoma, J Ito, ... BA 4, 2022.2005, 2022 | 48 | 2022 |
| Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA. 1, BA. 2, and BA. 5 T Tamura, D Yamasoba, Y Oda, J Ito, T Kamasaki, N Nao, R Hashimoto, ... Communications Biology 6 (1), 1-12, 2023 | 44 | 2023 |
| Genotype to phenotype Japan (G2P-Japan) consortium R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, ... Sawa, T. Ikeda, T. Irie, K. Matsuno, S. Tanaka, T. Fukuhara, K. Sato …, 2022 | 42 | 2022 |
Kei SatoProfessor. Division of Systems Virology, The Institute of Medical Science, The University of Tokyog.ecc.u-tokyo.ac.jp의 이메일 확인됨